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epartment of Biotechnology, Ministry of Science and Technology, Government of India, IndiaVaccines are widely recognized as one of medicine’s great-
st achievements. Without vaccinations, millions of children and
dults would contract a range of serious diseases that are now pre-
ented by vaccines, and many would have long-lasting effects, like
he polio affected children most older Indians grew up with, or
ven die. Vaccination is one of the most important tools in public
ealth, protecting individuals and communities from disease, and
he range of diseases that can be prevented by vaccines is expanding
cross and beyond infectious diseases. Research has shown there
re powerful links between population health and economic well-
eing. Childhood vaccination in particular is a valuable investment
ecause it not only reduces morbidity and mortality in a country
ut also promotes national economic growth and poverty reduction
1].
Until a few decades ago, new vaccines were developed and made
n the ﬁrst world, by large companies, who focused on the markets
rom which they could derive maximal return on investment. This
ed to a situation where the bulk of disease lay in poorer countries
hile the vaccine supply, limited in amount and by price, was
ainly in countries with low disease burden and high purchas-
ng power. The signiﬁcant lag in getting vaccines to children who
ost needed them was addressed by governments and interna-
ional agencies such as UNICEF and the WHO  Expanded Programme
f Immunization, who sought to widen the reach of vaccines to chil-
ren everywhere, with some but limited success. With the launch of
he GAVI Alliance in 2000, vaccine uptake improved and has contin-
ed to improve in developing countries. Vaccination rates against
he six key diseases have increased from around 20% in 1980 to
pproximately 80% in 2009, and the burden of vaccine-preventable
iseases has dropped dramatically [2].
However, beyond the six diseases targeted initially, are a range
f infectious diseases that continue to cause high levels of morbid-
ty and mortality in several parts of the world for which vaccines
xist or can be developed, if resources are available. Particularly
or countries like India, where respiratory infection and diarrhoea
ach contribute >10% to the mortality burden in young children
3], there is a need for safe, effective and affordable vaccines for use
n the public health system. Investments in vaccine development
equire an appetite for risk taking and long term investment, given
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264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Bthat failures are to be expected in translating academic success to
marketable products.
An outstanding example of the new world paradigm in afford-
able, safe and effective vaccine development is the Rotavac vaccine.
As with most vaccine candidates, the story began with an aca-
demic institution, the All India institute of Medical Sciences (AIIMS),
where in the 1980s, M.K. Bhan noticed that a strain of rotavirus
produced asymptomatic infections in neonates in the nursery and
protected them from subsequent disease. He started an informal
joint research program with Roger Glass, who worked initially in
Bangladesh and later at the Centers for Disease Control and Preven-
tion (CDC) in Atlanta and at the National Institutes of Health (NIH).
In 1989–1990, they attracted research support from the Depart-
ment of Biotechnology (DBT), Ministry of Science and Technology,
Government of India and NIH, under the joint Indo-US Vaccine
Action Program (VAP), and went to work on further characteri-
zation of this unusual neonatal strain, now known as 116E. The
116E strain was identiﬁed to be a human bovine reassortant, with a
bovine derived surface protein. Almost in parallel, another bovine-
human reassortant infecting neonates, I321, was described from
Bangalore, by Durga Rao of the Indian Institute of Science (IISc)
working with Harry Greenberg from Stanford University [4].
The NIH contracted with DynCorp to produce clinical-grade pilot
lots of the vaccines in 1997 and evaluate those lots in American
adults and children prior to shipping them to India. In 1998, the
Indo-US VAP solicited commercial partners in India for the next
stage of development and identiﬁed Bharat Biotech International
Ltd. (BBIL), a Hyderabad-based vaccine manufacturing company,
to develop both vaccine candidates. In 2000, a consortium of aca-
demic, public and private partners including BBIL, CDC, NIH, AIIMS,
Stanford University, and IISc, submitted a proposal to PATH and DBT
for support to move the two  vaccine candidates through produc-
tion, testing, and surveillance, with PATH joining the collaborative
effort through the Bill and Melinda Gates Foundation-funded Chil-
dren’s Vaccine Program.
This was  a unique group, bringing together an unusual combi-
nation of domestic and international partners, committed to social
innovation with a clear goal of developing a safe and effective vac-
cine that would reach the populations that most needed it at an
affordable price. In 2003, BBIL Bharat convened the various partners
to discuss the clinical development plan for the 116E and I321 vac-
cine lots. Trials conducted in 2005 showed that while both of them
were safe, 116E provided signiﬁcantly better immune response
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o the vaccine [5]. The development was then taken forward to
ate phase II and then phase III with the 116E candidate, under
he leadership of Nita Bhandari at the Society for Applied Studies,
 non-governmental organization formed of researchers formerly
t AIIMS, committed to child health research. The partners then
xpanded to include researchers at the KEM hospital and Research
entre, Pune and the Christian Medical College, Vellore to carry
ut the phase III clinical trial for efﬁcacy that required recruitment
f 6800 infants and their follow up for a period of two years, and
he Translational Health Science and Technology Institute, Delhi
o analyze all the clinical samples. The clinical trial was  carried
ut to the highest international standards, with remarkably low
oss to follow up, a critical determinant of trial quality. In addi-
ion, the intensive monitoring and follow up of participants and
rovision of access to medical care and referrals resulted in lower
han expected numbers of deaths at all three sites, pointing to the
ttention paid to participant safety in the trial. Despite the early
reatment and referrals, the data indicate that 116E based vaccine
now known as Rotavac) provided a level of protection (56% dur-
ng the ﬁrst year) comparable to other licensed rotavirus vaccines
n developing countries [6] which did not drop signiﬁcantly in the
econd year of life [7].
The sharing of the costs of development between several part-
ers played a crucial role in the ability to limit the price of the
accine to just $1 per dose. BBIL invested in a highly efﬁcient man-
facturing process and innovative product development efforts,
hich also contribute to keeping the costs low.
This joint, very collaborative, effort has been a new paradigm for
nnovation in strategy and process and has resulted in the availabil-
ty of safe and effective product for Indian and other developing
ountry markets. The deployment of this product now requires
urther partnerships—in consideration of the introduction of the
accine into the public health system and in continued safety
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surveillance. No vaccine is 100% safe, and with other licensed,
available rotavirus vaccines, a small (1 in 20,000–100,000) risk
of intussusception has been seen in post-marketing surveillance
and additional safety studies carried out by a number of agen-
cies, including the CDC and the immunization programs of several
countries. For countries such as India, continued engagement from
governmental agencies is necessary to generate and to effectively
use evidence for public health decision-making.
The Rotavac development effort is one that can and should be
emulated for other vaccines and by other vaccine manufacturers.
The government support and endorsement, national partnerships,
international collaboration and trust, all brought value that should
not be underestimated in this effort to develop a vaccine for India
and the world.
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